Sun Pharma sues Zydus Cadila for trademark violation

Published on Tue, Nov 10, 2009 at 18:38 |  Source : CNBC-TV18

Updated at Wed, Nov 11, 2009 at 13:23  

24312 Investors following Sun Pharma. Share this News with them.
0
0
Share on Tumblr

There's a new pharma battle brewing. Sun Pharma citing trademark violations by Zydus Cadila has got an ex parte injunction from the Madras High Court against the sale of Zydus Cadila's anti-depressant drug Venz, reports CNBC-TV18's Divya Rajagopal.
Here is a verbatim transcript of Divya Rajagopal's comments on CNBC-TV18. Also watch the accompanying video. 
Sun Pharmaceutical's has dragged Zydus Cadila for trademark violation of Sun Pharma's anti-depressant named Veniz. Zydus Cadila has launched a similar anti-depressant drug by the name of Venz. The Madras High Court has ordered an ex parte interim injunction against Zydus Cadila and has ordered that Zydus Cadila cannot sell its anti-depressant drug Venz till the time it is sorted out.
Sun Pharma has been selling Veniz over the last 10 years and is one of the major contributors for Sun Pharma's business. The next hearing will take place some time during the next week.

  

Entities: Divya
More on Moneycontrol

Trending News

Business News

6 ways to backup mobile data
Forget the IIP: there's free cash oozing out of every pore "Forget the IIP: there's free cash oozing out of every pore "

DLF Says Macro Environment Unfavourable W/High Comm & Labour Inflation

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com